All In Biotech

Drug Trial Radar · NCT02434861

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (1.8 mg/mL Rolapitant IV Solution) on the Pharmacokinetics of Digoxin (P-gp); Sulfasalazine (BCRP); and the Cooperstown Cocktail (Midazolam [CYP3A4], Omeprazole [CYP2C19], Warfarin [CYP2C9], Caffeine [CYP1A2], and Dextromethorphan [CYP2D6]) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

102

Actual

Start

May 2015

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Tesaro, Inc.GSK (GSK)
Sponsor type
Industry
First posted
May 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple cytochrome P450 (CYP) probe substrates in a healthy adult population.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

  • RolapitantDrug

  • DigoxinDrug

    P-gp substrate

  • SulfasalazineDrug

    BCRP substrate

  • Cooperstown CocktailDrug

    Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC: area under the plasma concentration-time curveTime frame: Predose - up to 120 hours postdose
  2. Cmax = observed maximum plasma concentrationTime frame: Predose - up to 120 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel Early Phase Unit

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.